NASH

Sep 04, 2024

Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll o...

Jun 11, 2024

Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...

Mar 19, 2024

Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna’s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owne...

Jul 07, 2023

Liver cirrhosis is a chronic and progressive condition characterized by the gradual replacement of healthy liver tissue with scar tissue, known as fibrosis. This scarring disrupts the normal structure and function of the liver. It also leads to symptoms such as confusion, ascites, pruritus, weakness, fatigue, and b...

Oct 04, 2022

Zealand Pharma Announces the Positive Topline Results from its Phase III trial of Glepaglutide Zealand Pharma A/S, a biotech company specializing in peptide-based medicines, announced positive topline results from its phase III trial of glepaglutide. In the evenly randomized double-blind trial, 106 patients with...

Sep 20, 2022

AstraZeneca’s Danicopan Shows Positive Results in Phase III Trial Danicopan, an oral Factor D inhibitor developed by AstraZeneca, was expected to fail a phase II trial in rare kidney disease in 2020, but a new readout could revive the drug. Danicopan (ALXN2040) has demonstrated efficacy as an adjunct treatment f...

Jun 29, 2021

A New Dawn for CRISPR, Intellia Edits Cells Inside the Body Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cells inside the body leveraging the CRISPR technique. The world’s first-ever trial that has their DNA edited through an in...

May 25, 2021

TLX66 Meets Study Objectives, Holding Out in AL Amyloidosis Telix Pharmaceuticals reported the results from the TRALA trial (Targeted Radiotherapy for AL Amyloidosis), a Phase I/IIa trial evaluating the safety and toxicity of TLX66 as the sole bone marrow conditioning agent prior to autologous hematopoietic stem...

Dec 15, 2020

Gannex received US FDA fast track designation for its NASH drug, ASC42 an FXR Agonist Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). The FTA designation will help the pharma company to advance its research and development...

Jul 16, 2020

Orchard licenses the gene therapy technology from GlaxoSmithKline  Orchard Therapeutics has permitted lentiviral stable cell line technology from GlaxoSmithKline for its use in hematopoietic stem cell gene therapies. GSK filed for patents on the tech before selling its rare disease gene therapy portfolio to...